<DOC>
	<DOC>NCT02688998</DOC>
	<brief_summary>In the REaCT-Vascular Access Her2 negative study, the investigator will use a novel method to allow comparisons of established standard of care vascular access strategies using the "integrated consent model" as part of a pragmatic clinical trial. Determining the optimal vascular access strategy remains an important medical issue for patients, nurses, physicians and society. A novel method to allow comparison of established standards of care is needed as part of an increasing internationally mandated incentive to perform more pragmatic clinic trials.</brief_summary>
	<brief_title>REaCT-vascular Access Her2 Negative Vascular Access Strategies for (Neo) Adjuvant Breast Cancer Treatment Without Trastuzumab</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirmed primary breast cancer Planned to start either FECD, ACD, dosedense ACT, TAC, or TC chemotherapy, in the adjuvant or neoadjuvant setting. ≥19 years of age Able to provide verbal consent • Contraindication to central line placement.</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HER2 negative</keyword>
</DOC>